Hoffman KE, et al. - Researchers report patient-reported outcomes (PROs) from a randomized trial, wherein urinary, bowel, and sexual function as reported by patients prior to treatment and at 2, 3, 4, and 5 years after treatment were compared between men who received either conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6 Gy in 1.8 Gy fractions) or dose-escalated hypofractionated IMRT (HIMRT, 72 Gy in 2.4 Gy fractions) for localized prostate cancer. In the patient group treated with dose-escalated intensity-modulated prostate radiation therapy using a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions), no increase in patient-reported urinary, bowel, and sexual symptom burden was found, relative to conventionally fractionated radiation group.